Combination Treatment With p53 Reactivator Yields High Clinical Response in TP53-Mutant Myelodysplastic Syndromes
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.